684 related articles for article (PubMed ID: 28643779)
1. Drugging the 'undruggable' cancer targets.
Dang CV; Reddy EP; Shokat KM; Soucek L
Nat Rev Cancer; 2017 Aug; 17(8):502-508. PubMed ID: 28643779
[TBL] [Abstract][Full Text] [Related]
2. Taking Aim at the Undruggable.
Coleman N; Rodon J
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-8. PubMed ID: 33989024
[TBL] [Abstract][Full Text] [Related]
3. Strategies for targeting undruggable targets.
Zhang G; Zhang J; Gao Y; Li Y; Li Y
Expert Opin Drug Discov; 2022 Jan; 17(1):55-69. PubMed ID: 34455870
[TBL] [Abstract][Full Text] [Related]
4. Drugging "undruggable" genes for cancer treatment: Are we making progress?
Duffy MJ; Crown J
Int J Cancer; 2021 Jan; 148(1):8-17. PubMed ID: 32638380
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in cancer drug discovery targeting RAS.
Wilson CY; Tolias P
Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
[TBL] [Abstract][Full Text] [Related]
6. Drugging Undruggable Molecular Cancer Targets.
Lazo JS; Sharlow ER
Annu Rev Pharmacol Toxicol; 2016; 56():23-40. PubMed ID: 26527069
[TBL] [Abstract][Full Text] [Related]
7. Drugging RAS: Know the enemy.
Papke B; Der CJ
Science; 2017 Mar; 355(6330):1158-1163. PubMed ID: 28302824
[TBL] [Abstract][Full Text] [Related]
8. Drugging the undruggable proteins in cancer: A systems biology approach.
Pathmanathan S; Grozavu I; Lyakisheva A; Stagljar I
Curr Opin Chem Biol; 2022 Feb; 66():102079. PubMed ID: 34426091
[TBL] [Abstract][Full Text] [Related]
9. Mission Possible: Advances in MYC Therapeutic Targeting in Cancer.
Allen-Petersen BL; Sears RC
BioDrugs; 2019 Oct; 33(5):539-553. PubMed ID: 31392631
[TBL] [Abstract][Full Text] [Related]
10. RAS-targeted therapies: is the undruggable drugged?
Moore AR; Rosenberg SC; McCormick F; Malek S
Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145
[TBL] [Abstract][Full Text] [Related]
11. Drugging the 'undruggable'. Therapeutic targeting of protein-DNA interactions with the use of computer-aided drug discovery methods.
Radaeva M; Ton AT; Hsing M; Ban F; Cherkasov A
Drug Discov Today; 2021 Nov; 26(11):2660-2679. PubMed ID: 34332092
[TBL] [Abstract][Full Text] [Related]
12. Drugging the undruggable RAS: Mission possible?
Cox AD; Fesik SW; Kimmelman AC; Luo J; Der CJ
Nat Rev Drug Discov; 2014 Nov; 13(11):828-51. PubMed ID: 25323927
[TBL] [Abstract][Full Text] [Related]
13. Drugging K-Ras
Ni D; Li X; He X; Zhang H; Zhang J; Lu S
Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
[TBL] [Abstract][Full Text] [Related]
14. Ras proteins as therapeutic targets.
Chakraborty A; Linnane E; Ross S
Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
[TBL] [Abstract][Full Text] [Related]
15. Synthetic lethality as an engine for cancer drug target discovery.
Huang A; Garraway LA; Ashworth A; Weber B
Nat Rev Drug Discov; 2020 Jan; 19(1):23-38. PubMed ID: 31712683
[TBL] [Abstract][Full Text] [Related]
16. Direct inhibition of RAS: Quest for the Holy Grail?
Spencer-Smith R; O'Bryan JP
Semin Cancer Biol; 2019 Feb; 54():138-148. PubMed ID: 29248537
[TBL] [Abstract][Full Text] [Related]
17. Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.
Mattox TE; Chen X; Maxuitenko YY; Keeton AB; Piazza GA
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31878223
[TBL] [Abstract][Full Text] [Related]
18. Fragment-based drug discovery supports drugging 'undruggable' protein-protein interactions.
Wang ZZ; Shi XX; Huang GY; Hao GF; Yang GF
Trends Biochem Sci; 2023 Jun; 48(6):539-552. PubMed ID: 36841635
[TBL] [Abstract][Full Text] [Related]
19. Advances in non-covalent based inhibitors targeting Myc: a promising approach for cancer treatment.
Singh VK; Rajak N; Giri R; Garg N
Future Med Chem; 2024 Jan; 16(2):101-103. PubMed ID: 38084612
[No Abstract] [Full Text] [Related]
20. MYC modulators in cancer: a patent review.
Wang XN; Su XX; Cheng SQ; Sun ZY; Huang ZS; Ou TM
Expert Opin Ther Pat; 2019 May; 29(5):353-367. PubMed ID: 31068032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
